comparemela.com

Latest Breaking News On - Erik skullerud - Page 5 : comparemela.com

Nordic Nanovector Provides update on PARADIGME, its Phase 2b Pivotal Trial with Betalutin® in R/R Follicular Lymphoma

/PRNewswire/ Nordic Nanovector ASA (OSE: NANOV) provides an update on the timeline for PARADIGME, its ongoing pivotal Phase 2b trial of Betalutin® (177Lu.

Erik skullerudMalene brondbergFrazer hall mediNordic nanovectorChief executive officerFrazer hall

Nordic Nanovector appoints Experienced International Life Sciences Executive Sandra Jonsson as Chief Operating Officer

/PRNewswire/ Nordic Nanovector ASA (OSE: NANOV), a clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune.

Uppsala lanMarco renoldiFrazer hall davidErik skullerudSandra jonssonMalene brondbergUppsala universityAlexion pharmaceuticalsUniversity of st gallenStockholm universityNordic nanovectorChief operatingLife scienceSenior directorCommercial internationalCommercial strategy

Nordic Nanovector appoints Experienced International Life Sciences Executive Sandra Jonsson as Chief Operating Officer

/PRNewswire/ Nordic Nanovector ASA (OSE: NANOV), a clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune.

Uppsala lanMarco renoldiFrazer hall davidErik skullerudSandra jonssonMalene brondbergUppsala universityAlexion pharmaceuticalsUniversity of st gallenStockholm universityNordic nanovectorChief operatingLife scienceSenior directorCommercial internationalCommercial strategy

Nordic Nanovector appoints Experienced International Life Sciences Executive Sandra Jonsson as Chief Operating Officer

OSLO, Norway, Dec. 16, 2021 /PRNewswire/ Nordic Nanovector ASA (OSE: NANOV), a clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune diseases

Uppsala lanMarco renoldiFrazer hall davidErik skullerudSandra jonssonMalene brondbergUppsala universityAlexion pharmaceuticalsUniversity of st gallenStockholm universityChief operatingLife scienceNordic nanovectorSenior directorCommercial internationalCommercial strategy

Nordic Nanovector to Present at DNB s 12th Nordic Healthcare Conference

OSLO, Norway, Dec. 8, 2021 /PRNewswire/ Nordic Nanovector ASA (OSE: NANOV), clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune diseases

Frazer hall davidErik skullerudMalene brondbergNordic healthcare conferenceDavid dibleNordic nanovectorSecurities trading

vimarsana © 2020. All Rights Reserved.